The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
89Bio Inc | Common | 282559103 | 11,264,517 | 967,742 | SH | SOLE | 967,742 | 0 | 0 | ||
Adaptimmune Therapeutics plc | Sponsored ADR | 00653A107 | 8,051,541 | 5,095,912 | SH | SOLE | 5,095,912 | 0 | 0 | ||
Akero Therapeutics Inc | Common | 00973Y108 | 8,409,660 | 332,924 | SH | SOLE | 332,924 | 0 | 0 | ||
ALX Oncology Holdings Inc. | Common | 00166B105 | 14,143,452 | 1,268,471 | SH | SOLE | 1,268,471 | 0 | 0 | ||
Amicus Therapeutics Inc. | Common | 03152W109 | 8,469,467 | 718,970 | SH | SOLE | 718,970 | 0 | 0 | ||
Avadel Pharmaceuticals PLC | Sponsored ADR | 05337M104 | 14,713,707 | 871,149 | SH | SOLE | 871,149 | 0 | 0 | ||
Axsome Therapeutics, Inc. | Common | 05464T104 | 9,107,335 | 114,127 | SH | SOLE | 114,127 | 0 | 0 | ||
Compass Therapeutics, Inc. | Common | 20454B104 | 3,903,376 | 1,971,402 | SH | SOLE | 1,971,402 | 0 | 0 | ||
Crinetics Pharmaceuticals Inc. | Common | 22663K107 | 22,496,324 | 480,588 | SH | SOLE | 480,588 | 0 | 0 | ||
Cullinan Oncology, Inc. | Common | 230031106 | 130,326,487 | 7,648,268 | SH | SOLE | 7,648,268 | 0 | 0 | ||
Disc Medicine Inc | Common | 254604101 | 6,897,101 | 110,779 | SH | SOLE | 110,779 | 0 | 0 | ||
Edgewise Therapeutics Inc | Common | 28036F105 | 8,048,564 | 441,259 | SH | SOLE | 441,259 | 0 | 0 | ||
Fulcrum Therapeutics Inc | Common | 359616109 | 10,734,300 | 1,137,108 | SH | SOLE | 1,137,108 | 0 | 0 | ||
Geron Corporation | Common | 374163103 | 34,569,728 | 10,475,675 | SH | SOLE | 10,475,675 | 0 | 0 | ||
Immatics NV | Common | N44445909 | 4,153,941 | 395,237 | SH | SOLE | 395,237 | 0 | 0 | ||
Insmed Incorporated | Common | 457669307 | 14,400,441 | 530,794 | SH | SOLE | 530,794 | 0 | 0 | ||
Intellia Therapeutics, Inc. | Common | 45826J105 | 11,900,771 | 432,598 | SH | SOLE | 432,598 | 0 | 0 | ||
Iovance Biotherapeutics Inc | Common | 462260100 | 32,604,000 | 2,200,000 | SH | SOLE | 2,200,000 | 0 | 0 | ||
Kalvista Pharmaceuticals Inc | Common | 483497103 | 9,022,163 | 760,722 | SH | SOLE | 760,722 | 0 | 0 | ||
iTeos Therapeutics, Inc. | Common | 46565G104 | 23,814,663 | 1,745,943 | SH | SOLE | 1,745,943 | 0 | 0 | ||
Madrigal Pharmaceuticals inc | Common | 558868105 | 16,395,989 | 61,399 | SH | SOLE | 61,399 | 0 | 0 | ||
Moonlake Immunotherapeutics | Class A Ord | 61559X104 | 14,870,592 | 296,050 | SH | SOLE | 296,050 | 0 | 0 | ||
MORPHIC HOLDING INC | Common | 61775R105 | 11,451,722 | 325,333 | SH | SOLE | 325,333 | 0 | 0 | ||
Natera Inc | Common | 632307104 | 15,768,893 | 172,413 | SH | SOLE | 172,413 | 0 | 0 | ||
Olema Pharmaceuticals, Inc. | Common | 68062P106 | 22,115,771 | 1,953,690 | SH | SOLE | 1,953,690 | 0 | 0 | ||
REGENXBIO Inc. | Common | 75901B107 | 11,569,073 | 549,078 | SH | SOLE | 549,078 | 0 | 0 | ||
Relay Therapeutics Inc. | Common | 75943R102 | 6,905,741 | 832,017 | SH | SOLE | 832,017 | 0 | 0 | ||
Repare Therapeutics, Inc. | Common | 760273102 | 7,723,689 | 1,639,849 | SH | SOLE | 1,639,849 | 0 | 0 | ||
Revolution Medicines, Inc. | Common | 76155X100 | 8,805,784 | 273,217 | SH | SOLE | 273,217 | 0 | 0 | ||
Sutro Biopharma, Inc. | Common | 869367102 | 23,145,897 | 4,096,619 | SH | SOLE | 4,096,619 | 0 | 0 | ||
Trevi Therapeutics Inc | Common | 89532M101 | 4,626,312 | 1,340,960 | SH | SOLE | 1,340,960 | 0 | 0 | ||
Ultragenyx Pharmaceutical Inc | Common | 90400D108 | 11,466,597 | 245,590 | SH | SOLE | 245,590 | 0 | 0 | ||
Verve Therapeutics, Inc | Common | 92539P101 | 8,474,805 | 638,163 | SH | SOLE | 638,163 | 0 | 0 | ||
VIKING THERAPEUTICS INC | Common | 92686J106 | 12,300,000 | 150,000 | SH | SOLE | 150,000 | 0 | 0 | ||
Viridian Therapeutics Inc | Common | 92790C104 | 10,751,315 | 614,010 | SH | SOLE | 614,010 | 0 | 0 | ||
Xeris Biopharma Holdings Inc | Common | 98422E103 | 9,207,956 | 4,166,496 | SH | SOLE | 4,166,496 | 0 | 0 | ||
Werewolf Therapeutics, Inc. | Common | 95075A107 | 15,474,311 | 2,388,011 | SH | SOLE | 2,388,011 | 0 | 0 | ||
Zentalis Pharmaceuticals, Inc. | Common | 98943L107 | 23,895,044 | 1,516,183 | SH | SOLE | 1,516,183 | 0 | 0 |